Evaluating Latest Evidence and Treatment Targets in Moderate to Severe Atopic Dermatitis - Episode 4
Head-to-head Study of Upadacitnib and Dupilumab in Atopic Dermatitis (Level Up)
Published on:
An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.
- Head-to-head studies of systemic treatments and studies evaluating sequencing of systemic treatments are rare. Results of one such study, Level Up, were recently presented at RAD 2024. Can you describe the study briefly and discuss primary and secondary outcomes in phase 3b/4 study that compared upadacitnib and dupilumab (Level Up, RAD 2024)?
- What are implications of these results in everyday practice?
